All In Biotech

Drug Trial Radar · NCT06970743

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

153

Actual

Start

May 29, 2025

Primary completion

Nov 30, 2029

Study completion Nov 30, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • BGB-16673Drug

    Administered orally

  • BendamustineDrug

    Administered intravenously

  • RituximabDrug

    Administered intravenously

  • MethylprednisoloneDrug

    Administered intravenously

  • ChlorambucilDrug

    Administered orally

  • ObinutuzumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by IRCTime frame: Approximately 23 Months

Locations

56 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Peking University Peoples Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Sun Yat Sen University Cancer Center Huangpu Branch

    Guangzhou, Guangdong, China

  • Meizhou People Hospital

    Meizhou, Guangdong, China

  • Shenzhen Nanshan Peoples Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Red Cross Hospital of Yulin City

    Yulin, Guangxi, China

  • Guizhou Provincial Peoples Hospital

    Guiyang, Guizhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Harbin Medical Universitynangang Branch

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Xuchang Central Hospitalluminghu Branch

    Xuchang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Henan Provincial Peoples Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Taihe Hospital

    Shiyan, Hubei, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Yichang Central Peoples Hospital

    Yichang, Hubei, China

  • The First Peoples Hospital of Changde City

    Changde, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China

  • Qinghai University Affiliated Hospital

    Xining, Qinghai, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.